Challenges facing exosome therapy: standardization, manufacturing and regulation
The main obstacles between exosome research and approved products: loose terminology, hard-to-scale manufacturing, the FDA biologics pathway and open science questions.

Key takeaways.
- The word exosome is used loosely, so two studies may be describing different preparations.
- Primary MSCs vary between donors and batches, which complicates consistent manufacturing.
- In the US, exosomes are most commonly treated as biological drugs under Section 351.
- That pathway requires an IND for clinical trials and a BLA for marketing approval.
- Which cargo components drive any effect remains incompletely answered.
- Engineered exosomes with targeting and loaded cargo are a main future research direction.
The terminology problem
Strictly, an exosome is a vesicle formed inside the cell and released when a multivesicular body fuses with the cell membrane. Microvesicles bud directly from the membrane. Apoptotic bodies are released during programmed cell death.
In practice, many studies label a preparation as exosomes based mainly on size, without proof of origin. Preparations isolated by different methods can differ greatly in purity. Comparing results across such studies can be meaningless, even though both use the same word.
Manufacturing and scale
The choice of cell source shapes consistency, scalability and the regulatory path. Primary MSCs from bone marrow, adipose tissue, umbilical cord or placenta match the cells used in published studies.
They also have limits. Primary MSCs can only divide a finite number of times in culture. They vary from donor to donor and from batch to batch, which complicates quality control.
The regulatory pathway
Exosome products do not fit neatly into categories written before cell-free biologics existed. The most common classification in the United States treats them as biological drug products under Section 351 of the Public Health Service Act.
That means an Investigational New Drug (IND) application for clinical trials and a Biologics License Application (BLA) for marketing approval. Exosome therapies are not FDA-approved for therapeutic use.
Open questions and future directions
Basic questions remain. It is still not established which cargo components drive observed effects: proteins, microRNAs, other RNAs, lipids or combinations. Vesicles within one preparation also vary.
Future work is expected to focus on engineered exosomes. Approaches under development include surface modification for tissue targeting and loading vesicles with specific therapeutic molecules.
Educational content for healthcare professionals. Not a treatment recommendation. Exosome therapies are not FDA-approved for therapeutic use.
This guide covers the what and the why.
The how is taught live. The webinar and live training go deeper on:
- Characterization standards and what to ask a supplier
- Compliance requirements for clinics
- Manufacturing approaches and their trade-offs
- Emerging engineered exosome technologies
Common questions.
What is the difference between exosomes and extracellular vesicles?
How does the FDA regulate exosome products?
Why is exosome manufacturing hard to standardize?
Sources
- Théry, C., et al. (2018). Minimal information for studies of extracellular vesicles 2018 (MISEV2018). Journal of Extracellular Vesicles, 7(1), 1535750.
- Witwer, K. W., et al. (2019). Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. Journal of Extracellular Vesicles, 8(1), 1609206.
- Gimona, M., et al. (2017). Manufacturing of human extracellular vesicle-based therapeutics for clinical use. International Journal of Molecular Sciences, 18(6), 1190.
Keep reading.
Exosome · 2 min read
Personalized exosome therapy: why responses vary and what biomarkers could add
Why response to exosomes appears to vary between individuals, how disease stage may matter, and what predictive biomarkers are meant to do.
Start the lessonExosome · 3 min read
Ethics of offering exosome therapy: consent, cost and marketing
The ethical ground rules for clinicians considering exosomes: informed consent for an investigational therapy, patient selection, cost, honest marketing and competency.
Start the lessonExosome · 3 min read
What are exosomes?
Exosomes are nanoscale vesicles that cells release to carry proteins, RNA and lipids to other cells. Here is what they are, how they form and where they stand with the FDA.
Start the lessonReady for the hands-on detail?
Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.